Emerging Therapies Using Molecular Glues to Selectively Eliminate Pathogenic Proteins

Abstract

Molecular glues have emerged as a transformative strategy in targeted protein degradation, offering an innovative approach to selectively eliminate pathogenic proteins implicated in a wide range of diseases. By harnessing endogenous cellular degradation pathways, these small molecules induce proximity between E3 ubiquitin ligases and nefarious proteins, facilitating their ubiquitination and subsequent proteasomal degradation. This review critically examines the recent advances, clinical potential, and mechanistic basis of molecular glue therapies, with a focus on their application in oncology, neurodegenerative disorders, and other proteinopathies. Current evidence, clinical trial data, and expert perspectives are discussed to elucidate the paradigm shift these therapies represent in precision medicine and drug development.

Introduction

The therapeutic landscape for proteinopathies, including cancers and neurodegenerative diseases, has been revolutionized by the advent of targeted protein degradation technologies. Molecular glues constitute a novel class of small molecules that repurpose the cell’s ubiquitin-proteasome system (UPS) to induce selective degradation of disease-causing proteins. Unlike traditional inhibitors, which often suffer from resistance and off-target effects, molecular glues exploit endogenous cellular machinery to irreversibly remove pathogenic proteins from the proteome. This review explores the scientific underpinnings, recent clinical developments, and future prospects of molecular glue therapies, providing healthcare professionals with an in-depth understanding of their clinical utility and translational relevance.

Epidemiology / Disease Burden

Protein misfolding and aggregation underlie a significant burden of human disease, particularly in cancer, neurodegenerative, and rare genetic disorders. Aberrant proteins, including transcription factors, kinases, and aggregation-prone species like tau and alpha-synuclein, contribute to disease pathogenesis and progression. The global prevalence of such disorders is rising due to increased life expectancy and improved diagnostics. For example, hematological malignancies such as multiple myeloma and acute myeloid leukemia, diseases with significant mortality and morbidity, frequently harbor undruggable oncoproteins. Similarly, neurodegenerative diseases such as Alzheimer’s and Parkinson’s are characterized by the accumulation of deleterious proteins, representing an unmet clinical need for innovative therapeutic strategies capable of selective protein removal.

Pathophysiology

Pathogenic proteins exert their deleterious effects through diverse mechanisms, including aberrant signaling, loss of regulatory control, impaired cellular homeostasis, and toxic aggregate formation. In cancer, oncogenic transcription factors and kinases drive uncontrolled cell proliferation and resistance to apoptosis. In neurodegeneration, misfolded proteins escape normal quality control processes, leading to synaptic dysfunction and neuronal death. The inability of classical therapeutics to adequately address these targets is largely due to the lack of suitable binding pockets or the proteins’ essential structural roles, rendering them "undruggable" by conventional means. Molecular glues overcome these limitations by mediating novel protein–protein interactions, redirecting E3 ubiquitin ligases to specifically tag pathogenic proteins for destruction via the proteasome.

Risk Factors

Risk factors for diseases caused by pathogenic proteins are multifactorial. In oncology, genetic mutations, epigenetic dysregulation, environmental carcinogens, and chronic inflammation contribute to the aberrant expression of oncogenic proteins. Neurodegenerative diseases are associated with aging, genetic predispositions (e.g., APOE4 in Alzheimer’s), environmental toxins, and traumatic brain injury, all of which exacerbate protein misfolding and aggregation. Understanding these risk factors is critical for identifying patient populations that may benefit most from molecular glue therapies and for developing personalized treatment strategies.

Clinical Features

The clinical manifestations of diseases driven by pathogenic proteins are heterogeneous, reflecting the diverse functions of the proteins involved. In hematological malignancies, clinical features may include anemia, thrombocytopenia, recurrent infections, lymphadenopathy, and organomegaly. Neurodegenerative disorders present with cognitive impairment, motor dysfunction, behavioral changes, and progressive loss of autonomy. Importantly, the severity and progression of clinical symptoms are often correlated with the burden of pathogenic protein accumulation, underscoring the clinical relevance of targeted protein degradation strategies.

Diagnosis

Diagnostic approaches for identifying pathogenic protein-driven diseases rely on a combination of clinical evaluation, laboratory assays, molecular profiling, and advanced imaging. Techniques such as immunohistochemistry, mass spectrometry, next-generation sequencing, and biomarker quantification are routinely employed to detect and quantify aberrant proteins. In oncology, specific translocations or mutations may serve as diagnostic hallmarks (e.g., BCR-ABL in chronic myeloid leukemia). In neurodegeneration, cerebrospinal fluid analysis and PET imaging are instrumental in detecting protein aggregates. Accurate diagnosis is essential to stratifying patients who may benefit from molecular glue-based approaches.

Treatment & Management

Conventional management of proteinopathy-associated diseases includes small-molecule inhibitors, monoclonal antibodies, immunotherapies, and supportive care. However, these strategies often fall short due to target inaccessibility, development of resistance, or adverse effects. Targeted protein degradation offers a new therapeutic paradigm by directly eliminating pathogenic proteins rather than merely inhibiting their function. Molecular glues are distinguished by their ability to induce highly selective and irreversible protein degradation with potentially fewer off-target effects. Early clinical evidence suggests that these agents may provide robust efficacy in refractory or relapsed disease settings, particularly in patients who have exhausted standard options.

Recent Advances / Emerging Therapies

Molecular glues, exemplified by thalidomide analogs (IMiDs) such as lenalidomide and pomalidomide, have already demonstrated clinical success in multiple myeloma by promoting the degradation of Ikaros and Aiolos transcription factors through cereblon-mediated ubiquitination. Recent research has identified novel molecular glues capable of targeting previously intractable proteins, such as BCL6 in diffuse large B-cell lymphoma and BRD4 in solid tumors. High-throughput screening, structure-guided design, and proteomics have accelerated the discovery of next-generation molecular glues with enhanced specificity and potency. Early-phase clinical trials are investigating these compounds in hematological malignancies, solid tumors, and neurodegenerative diseases, with promising preliminary outcomes. Emerging modalities also include bifunctional degraders (PROTACs), which, while mechanistically distinct, share conceptual similarities with molecular glues and expand the therapeutic repertoire.

Guideline Recommendations

While formal guidelines for the use of molecular glues are still evolving, leading oncology and neurology societies recognize the potential of targeted protein degradation in refractory disease states. Clinical trial participation is currently recommended for eligible patients, particularly those with relapsed or refractory malignancies lacking effective standard-of-care treatments. Molecular profiling and biomarker-driven patient selection are essential to optimize therapeutic efficacy and minimize toxicity. As more data emerge from ongoing studies, incorporation of molecular glues into evidence-based practice guidelines is anticipated, particularly for diseases with high unmet medical need and clear pathogenic protein drivers.

Conclusion

Molecular glues represent a paradigm shift in the management of proteinopathy-associated diseases, offering a novel and highly selective approach to eradicate pathogenic proteins. By co-opting endogenous degradation pathways, these agents transcend the limitations of traditional inhibitors and expand the boundaries of druggable targets. Early clinical data underscore their promise in oncology, neurodegeneration, and beyond, with ongoing research poised to refine their specificity, safety, and therapeutic reach. Continued collaboration between translational researchers, clinicians, and regulatory agencies will be instrumental in realizing the full clinical potential of molecular glue therapies and integrating them into the standard of care for protein-driven diseases.